HCW Biologics Inc. announced that on March 3, 2025, the Nasdaq Hearings Panel granted the company an extension to regain compliance with all continued listing rules of The Nasdaq Capital Market. This decision followed a hearing held on February 13, 2025.
The Panel considered the company's plan to address non-compliance with Listing Rules 5450(a)(1) (minimum bid price), 5450(b)(2)(A) (market value of publicly held securities), and 5450(b)(2&3)(C) (market value of listed securities).
As a result of the extension, HCW Biologics must demonstrate compliance with the Bid Price Rule by April 25, 2025, and all other Exchange continued listing rules by June 15, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.